In men with newly diagnosed metastatic hormone-sensitive prostate cancer, adding lutetium-177 PSMA-617 (177 Lu-PSMA-617) to standard hormone therapy led to a statistically significant improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results